Can a Gastroenterologist Prescribe Semaglutide?
Yes, gastroenterologists can prescribe semaglutide—there is no FDA restriction limiting prescribing authority to cardiologists or endocrinologists only. The premise of your question appears to be based on a misunderstanding, as neither the FDA drug label nor current clinical guidelines restrict semaglutide prescribing to specific specialties 1.
Prescribing Authority
The FDA-approved labeling for semaglutide (both Ozempic for diabetes and Wegovy for obesity) contains no language restricting prescribing to cardiologists or endocrinologists 1. Any licensed physician with prescribing authority can legally prescribe semaglutide for FDA-approved indications.
Gastroenterology's Role in Obesity Management
The American Gastroenterological Association (AGA) explicitly endorses gastroenterologists prescribing GLP-1 receptor agonists, including semaglutide, for obesity management 2. The 2022 AGA Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity provides detailed recommendations for gastroenterologists to:
- Use semaglutide 2.4 mg subcutaneously weekly with lifestyle interventions for adults with obesity or overweight with weight-related complications 2
- Implement proper dose titration protocols starting at 0.25 mg weekly, escalating every 4 weeks to maintenance dose of 2.4 mg after 16 weeks 2
- Monitor for gastrointestinal adverse effects, which are particularly relevant to gastroenterology practice 2
Clinical Rationale for Gastroenterology Involvement
Gastroenterologists are particularly well-positioned to prescribe semaglutide because:
- GI adverse effects are the most common side effects (nausea 40-84%, vomiting 16%, diarrhea, constipation) 2, 3
- Gastroenterologists have expertise in managing gastroparesis and delayed gastric emptying, which are key mechanisms and potential complications of GLP-1 RAs 4
- The AGA guideline demonstrates the specialty's commitment to comprehensive obesity management 2
Important Prescribing Considerations
When prescribing semaglutide, any physician should:
- Screen for contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 2, 5
- Implement gradual dose titration to minimize GI adverse effects 2
- Monitor for pancreatitis and gallbladder disease, as GLP-1 RAs carry increased risk 2
- Counsel patients on realistic expectations: weight loss of approximately 10.8-13.9% with semaglutide 2.4 mg over 52-72 weeks 2, 6
- Consider cardiovascular benefits: semaglutide reduces major adverse cardiovascular events (HR 0.74,95% CI 0.58-0.95) 1
Common Pitfall to Avoid
Do not confuse specialty expertise with prescribing restrictions. While endocrinologists and cardiologists may have more experience with diabetes and cardiovascular disease management, this does not translate to exclusive prescribing authority. The multidisciplinary nature of obesity treatment means gastroenterologists, primary care physicians, and other specialists all have legitimate roles in prescribing semaglutide 7, 8, 5.
If you encountered language suggesting specialty restrictions, it likely came from institutional protocols, insurance requirements, or clinical pathways—not FDA regulations. Some healthcare systems may create internal guidelines preferring certain specialists, but these are administrative decisions, not legal requirements.